What Is Pfizer, Inc. (PFE) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Pfizer, Inc. at $24.48. With an estimated intrinsic value of $36.70 and 7 of 12 models pointing higher, the average implied return is +49.9%. The most optimistic model, EPV, places fair value at $73.85 (+201.7%), while Sentiment SOTP — the most conservative — estimates $6.97 (-71.5%). This +273.2% gap reflects genuine analytical uncertainty about Pfizer, Inc.'s intrinsic worth. Among models with highest confidence, Bayesian DCF, EPV lean bullish — adding weight to the bullish side of the thesis.
What Do the Models Say About PFE?
12 of 13 models are currently active for PFE. Of these, 9 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates PFE's intrinsic value at $51.21, implying +109.2% upside from the current price. See which stocks rank higher →
How Does PFE Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, PFE ranks #62 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Pfizer, Inc. competes in an environment where patent cliff exposure often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is PFE a Value Trap?
CirclFi's Value Trap algorithm assigns PFE a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Pfizer, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Pfizer, Inc.'s fundamental quality profile registers 6.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +273.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PFE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PFE's 12 active models, average confidence is 54%. Moderate confidence indicates reasonable fit.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad